Search alternatives:
significant validation » significant variation (Expand Search), significant variations (Expand Search), significant application (Expand Search)
validation process » evaluation process (Expand Search), fabrication process (Expand Search)
teer decrease » mean decrease (Expand Search), greater decrease (Expand Search)
_ decrease » _ decreased (Expand Search)
significant validation » significant variation (Expand Search), significant variations (Expand Search), significant application (Expand Search)
validation process » evaluation process (Expand Search), fabrication process (Expand Search)
teer decrease » mean decrease (Expand Search), greater decrease (Expand Search)
_ decrease » _ decreased (Expand Search)
-
1
-
2
-
3
-
4
-
5
-
6
-
7
-
8
FASN Expression in OA and RA–shows that FASN is also significantly downregulated in the disease groups for OA and RA, suggesting its decreased activity might influence disease mechanisms or progression.
Published 2024“…<p>FASN Expression in OA and RA–shows that FASN is also significantly downregulated in the disease groups for OA and RA, suggesting its decreased activity might influence disease mechanisms or progression.…”
-
9
-
10
Y-27632 collaborated with BA to attenuate the increase in the integrity and decrease in the permeability of epithelial barrier injury induced by LPS in Caco2 monolayers.
Published 2024“…<p>(<b>A)</b> Y-27632 collaborated with BA to attenuate the effect of LPS on TEER in Caco2 cells on days 1–22. (<b>B)</b> Y-27632 collaborated with BA to attenuate the effect of LPS on TEER in Caco2 cells on day 22. …”
-
11
-
12
-
13
-
14
Transepithelial electrical resistance (TEER) (N = 6).
Published 2024“…<p><b>(A)</b> During the cultivation of SMC and ALI we observed significantly differences on day 18 (SMC: 9.61 kΩ*cm<sup>2</sup>; ALI: 7.73 kΩ*cm<sup>2</sup>; p<0.05) and day 25 (SMC: 8.19 kΩ*cm<sup>2</sup>; ALI: 6.44 kΩ*cm<sup>2</sup>; p<0.05) ALI cultures showed significantly decreased values compared to SMC. …”
-
15
-
16
-
17
-
18
Evaluation process for the validation of SARS-COV-2 rapid diagnostic tests in Nigeria.
Published 2024Subjects: -
19
-
20